Drugs / NPC-15
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03475459 | Apr 2018 | short QT syndrome | Nobelpharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02757079 | Jun 2016 → Jul 2018 | neurodevelopmental disorder, sleep disorder | Nobelpharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPC-15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02757079 ↗ |
| Known as | melatonin | “NPC-15 (melatonin 8mg or 16mg)” NCT03475459 ↗ |
| Route | Oral | “is administered orally before going to bed” NCT02757079 ↗ |